Misplaced Pages

Linaprazan

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Pharmaceutical molecule Pharmaceutical compound
Linaprazan
Clinical data
Other namesAZD-0865
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 8--N-(2-hydroxyethyl)-2,3-dimethylimidazopyridine-6-carboxamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC21H26N4O2
Molar mass366.465 g·mol

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB). Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.

The drug was then licensed to Cinclus Pharma, which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself.

Chemical structure of linaprazan glurate

References

  1. Rawla P, Sunkara T, Ofosu A, Gaduputi V (December 2018). "Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?". World Journal of Gastrointestinal Pharmacology and Therapeutics. 9 (7): 63–68. doi:10.4292/wjgpt.v9.i7.63. PMC 6305499. PMID 30595950.
  2. "Linaprazan". Inxight Drugs. National Center for Advancing Translational Sciences.
  3. Tong A (4 March 2020). "Can reformulation of an AstraZeneca castoff rival Takeda's new heartburn drug? Here's a $26M bet on yes". endpts.com.
  4. ^ "Linaprazan glurate". Cinclus Pharma.
Drugs for peptic ulcer and GERD/GORD (A02B)
H2 antagonists ("-tidine")
Prostaglandins (E)/
analogues ("-prost-")
Proton-pump inhibitors
("-prazole")
Potassium-competitive
acid blockers ("-prazan")
Others
Combinations
Categories: